CASP1 and systemic lupus erythematosus: Recent research demonstrated VX-765 ameliorates vascular inflammation and atherosclerosis in a murine model of atherosclerosis,47 suggesting another potential therapeutic benefit of caspase-1 inhibition for SLE patients, as cardiovascular events are a significant cause of death in this population.